modelS01FA03
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Methylscopolamine | |
| ATC code: | S01FA03 | route: | oral |
| compartments: | 1 | |
| dosage: | 2.5 | mg |
| volume of distribution: | 1.5 | L |
| clearance: | 8.0 | L/h |
| other parameters in model implementation | ||
Methylscopolamine is a quaternary ammonium derivative of scopolamine, used as an antimuscarinic agent for the treatment of gastrointestinal disorders such as peptic ulcer, and for the reduction of salivation and respiratory secretions. It is less likely to cross the blood-brain barrier compared to scopolamine. Methylscopolamine is approved for use in several countries for these indications, primarily as adjunctive therapy.
Pharmacokinetics
Pharmacokinetic parameters estimated for adult population based on general physicochemical and pharmacological properties of quaternary ammonium antimuscarinics; no direct clinical PK data available in published human studies as of 2024.
References
Yoshida, A, et al., & Yamada, S (2011). Characterization of muscarinic receptors in the human bladder mucosa: direct quantification of subtypes using 4-DAMP mustard. Urology 78(3) 721.e7–721.e12. DOI:10.1016/j.urology.2011.05.011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21777958
Ek, B, & Nahorski, S (1988). Muscarinic receptor coupling to inositol phospholipid metabolism in guinea-pig cerebral cortex, parotid gland and ileal smooth muscle. Biochemical pharmacology 37(23) 4461–4467. DOI:10.1016/0006-2952(88)90661-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2849446
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)